Literature DB >> 25275934

A pilot study on the Psoriasis Area and Severity Index (PASI) for small areas: Presentation and implications of the Low PASI score.

M E Otero1, M J van Geel, J C M Hendriks, P C M van de Kerkhof, M M B Seyger, E M G J de Jong.   

Abstract

BACKGROUND: The Psoriasis Area and Severity Index (PASI) is not able to measure small affected areas in a body region which is important for assessing the performance of high-effective treatment.
OBJECTIVE: To present the Low PASI score, show the difference between the classic PASI and the Low PASI, evaluate the inter-observer agreement of both scores, and compare the two scores within investigators.
METHODS: Cross-sectional study. Two investigators independently assessed the classic PASI and the Low PASI in 10 patients with mild-to-moderate plaque psoriasis. Differences in outcome between the two scores were calculated. Intra-class correlation coefficients (ICC) were used to determine the inter-observer agreement and to compare measurements of the two scores within both investigators. Prediction limits of 95% for the errors in measurements were provided.
RESULTS: In both investigators, Low PASI was mean 1.71 and 1.76, whereas the classic PASI was mean 4.14 and 4.33. The inter-observer agreement (ICC) was excellent for both investigators in both scores (ICC classic PASI = 0.95 and Low PASI = 0.87).
CONCLUSION: The Low PASI score allows more possible scores at lower levels of psoriasis extent (affected areas lower than 10% in a body region) compared to the classic PASI. This new score may lead to a more precise analysis of treatment responses and may have important clinical implications.

Entities:  

Keywords:  Body surface area; PASI; Psoriasis Area and Severity Index; psoriasis

Mesh:

Year:  2014        PMID: 25275934     DOI: 10.3109/09546634.2014.972316

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  3 in total

Review 1.  Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action.

Authors:  Aina Akmal Mohd Noor; Maryam Azlan; Norhanani Mohd Redzwan
Journal:  Biomedicines       Date:  2022-02-20

2.  Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.

Authors:  Selma Atalay; Lara S van der Schoot; Laura Vandermaesen; Lieke J van Vugt; Mascha Eilander; Juul M P A van den Reek; Elke M G J de Jong
Journal:  Acta Derm Venereol       Date:  2021-05-25       Impact factor: 3.875

3.  A Controlled Study of the Feasibility and Efficacy of a Cloud-Based Interactive Management Program Between Patients with Psoriasis and Physicians.

Authors:  Beibei Zhu; Yanyan Wang; Xuan Zhou; Chunyan Cao; Yan Zong; Xiaodan Zhao; Zuohong Sha; Xiaoyun Zhao; Shanhang Han
Journal:  Med Sci Monit       Date:  2019-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.